Amorfix and Ontario Genomics Institute announce partnership to accelerate development of blood test for Alzheimer's Disease

02-Feb-2006

Amorfix Life Sciences Inc. and the Ontario genomics Institute (OGI) announced they are entering into a partnership to develop a blood test for Alzheimer's disease, EP-AD(TM), based upon Amorfix's patent-pending Epitope Protection technology. OGI will assist Amorfix in accelerating its program for diagnosis of neurodegenerative diseases drawing on OGI's portfolio of state-of-the-art genomics and proteomics facilities, research and pre-commercial development in Ontario.

Dr. Neil Cashman, Amorfix's CSO said, "Until now, it has been very difficult to detect aggregated misfolded proteins in blood where normal protein is prevalent. With our progress on the Epitope Protection platform, we are now in a position to finish our development of a test for Alzheimer's A-beta aggregates in blood."

Pursuant to a term sheet executed December 22, 2005, OGI has executed a subscription agreement to invest $100,000 in Amorfix to accelerate the EP-AD(TM) project. OGI will, upon closing, invest $50,000 receiving 100,000 common shares of AMF and 50,000 warrants to purchase shares for $.90 for a term of two years. Upon the achievement of a defined research milestone, OGI will invest $50,000 at market price and receive a one-half warrant for each share purchased to purchase a share at the then market price within 2 years. This transaction is subject to acceptance for filing by the TSX Venture exchange.

Other news from the department science

Most read news

More news from our other portals

Last viewed contents

New Head of Marketing Communications and PR at JULABO

New test improves diagnosis of allergies - Higher diagnostic accuracy than standard tests

New test improves diagnosis of allergies - Higher diagnostic accuracy than standard tests

HeartBeat.bio raises € 4.5 million in Pre-Series A financing - New funds to drive development of organoid screening platform for cardiac drug discovery

HeartBeat.bio raises € 4.5 million in Pre-Series A financing - New funds to drive development of organoid screening platform for cardiac drug discovery

New computer vision system designed to analyse cells in microscopy videos

New computer vision system designed to analyse cells in microscopy videos

Musical sensor shows bad medicine plays false note - Inspired by a musical instrument, the simple sensor can be constructed from common materials and used to detect adulterated or counterfeit drugs

Musical sensor shows bad medicine plays false note - Inspired by a musical instrument, the simple sensor can be constructed from common materials and used to detect adulterated or counterfeit drugs

PerkinElmer and University of Copenhagen Announce Licensing Agreement for New Maternal Health Marker ADAM12

How can we fight blood cancer more effectively? - Several hundred different treatment combinations to be tested simultaneously outside the body

How can we fight blood cancer more effectively? - Several hundred different treatment combinations to be tested simultaneously outside the body

LGC announces plans to expand forensic services with new facilities to be created in Runcorn, Cheshire

Synthetic Production of Potential Pharmaceuticals Dramatically Simplified by Scripps Research Team - Findings Could Expand Interest in Natural Products by Making Production More Cost-Effective

Light-induced shape shifting of MXenes - Femtosecond light creates switchable nano-waves in MXenes and moves the materials’ atoms at a record-breaking speed

Light-induced shape shifting of MXenes - Femtosecond light creates switchable nano-waves in MXenes and moves the materials’ atoms at a record-breaking speed

Brooks Instrument Joins Major Biotechnology Consortium Focused on Regenerative Drug Manufacturing - Brooks Instrument will contribute insights and precision fluid control technology to the Advanced Regenerative Manufacturing Institute’s BioFabUSA program

Brooks Instrument Joins Major Biotechnology Consortium Focused on Regenerative Drug Manufacturing - Brooks Instrument will contribute insights and precision fluid control technology to the Advanced Regenerative Manufacturing Institute’s BioFabUSA program

Promising discovery for a non-invasive early detection of Alzheimer's disease

Promising discovery for a non-invasive early detection of Alzheimer's disease